Shanghai Haohai Biological Technology Co., Ltd. (a joint stock company in the People’s Republic of China) announced key share information as of November 13, 2025. The number of H shares remained at 38,529,240 before and after the relevant dates, with no changes in the total balance. In its A share segment, the company maintained 190,203,760 issued shares and 3,848,095 treasury shares, bringing the total to 194,051,855 shares.

According to the disclosure, multiple H-share repurchases were executed from September to November 2025. The most recent occurred on November 13, 2025, involving 39,500 H shares at a repurchase price of HKD 28.04. These repurchased shares have not yet been cancelled as of the disclosure date. Under the current repurchase mandate approved on June 10, 2025, Shanghai Haohai Biological is authorized to repurchase up to 3,914,184 H shares. As of November 13, 2025, 580,100 H shares had been repurchased, representing approximately 1.482% of the total H shares outstanding at the time the mandate was granted. The issuer indicated a moratorium period until December 13, 2025, during which no new H shares will be issued or transferred from treasury pursuant to the rules governing share repurchases.